JMP Securities analyst Jason Butler raised the firm’s price target on Rezolute (RZLT) to $9 from $8 and keeps an Outperform rating on the shares. Rezolute reported Q2 results and business updates, with the Phase 3 sunRIZE trial for ersodetug in congenital hyperinsulinism continuing to enroll, and progress remains on track to begin enrolling U.S. patients in the second quarter of 2025, the analyst tells investors in a research note. The firm looks to the outcome of the planned interim analysis for this trial in early 2Q25.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RZLT:
- Rezolute reports Q2 EPS (22c), consensus (26c)
- Rezolute’s Advancements in CHI Treatment and Strategic Positioning Justify Buy Rating with $14 Target
- Promising Developments in Rezolute’s cHI Treatment Drive Buy Rating
- Rezolute Advances SunRIZE Study for Hypoglycemia Treatment
- Rezolute provides update on Phase 3 sunRIZE study on ersodetug